Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • US House passes debt ceiling bill in crucial step to avert historic default
    • Earth past its safe limits for humans, scientists say
    • Eurozone inflation falls to lowest level since Russia invaded Ukraine
    • ‘Faith in the Speaker’: Kevin McCarthy defies critics with US debt ceiling win
    • ‘People rot from the inside out’: lethal xylazine deepens the US drug crisis
  • UK
    Sections
    • UK Home
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
    Most Read
    • UK house prices extend falls as mortgage repayments soar
    • UK government takes legal action over Johnson’s Covid messages
    • Insurer for English barristers paid £750,000 to own director to fight cases
    • UK should boost alignment of rules with EU, says business commission
    • Labour suspends MP Geraint Davies over claims of ‘unacceptable’ behaviour
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • ‘Everyone will get affected’: Tesla jolts EV charging industry
    • ‘Ultimate decider’ on Jeffrey Epstein was JPMorgan’s ex-top lawyer, says Jamie Dimon
    • Canadian pension fund CDPQ puts brakes on China investment
    • BHP to pay $280mn after underpaying 30,000 staff for years
    • Goldman warns of new job cuts in ‘tougher environment’ on Wall Street
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • Live news updates from June 1: US retailers warn on consumer spending, SpaceX wins Pentagon contract
    • Exxon and Chevron shareholders cut support for climate resolutions
    • Resilient US junk bond market baffles investors
    • Opec bans prominent media groups from Vienna meeting
    • Loan market braced for rush to Libor finish line
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
    Most Read
    • We should stop worshipping at the altar of convenience
    • How the Thatcherites lost their Brexit dream and their party
    • Beware ‘death by GPT syndrome’
    • Game, set and almost match to Biden on the debt ceiling
    • Why Wall Street is trying to shake up the 2024 race
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • ‘Everyone has the right to completely log off’: what bosses think about the right to disconnect
    • Wellcome Leap’s Regina Dugan: ‘Odds are irrelevant, if what you’re trying to do is important’
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Porsche, Bentley, Armani: Why Miami can’t build enough branded high rises
    • Bruce Springsteen battles mortality in three-hour Edinburgh show
    • Trump or not, US meltdown could be inevitable
    • The UK’s best bakeries: the readers’ picks
    • It’s time to reconsider the shirt collar
  • HTSI
MenuSearch
  • Home
  • World
  • UK
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Eisai Co Ltd

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Monday, 8 May, 2023
    Dementia
    Two Alzheimer’s drugs offer hope to patients after decades of waiting

    In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide

  • Wednesday, 11 January, 2023
    Anjana Ahuja
    New Alzheimer’s drug straddles uneasy gulf between help and harm

    For all its landmark status, lecanemab may end up representing a triumph of hope over evidence

  • Friday, 6 January, 2023
    Pharmaceuticals sector
    US approves Alzheimer’s drug that slows rate of cognitive decline

    High price of treatment and restrictions on medicine developed by Eisai and Biogen will limit patient access initially

  • Friday, 2 December, 2022
    Pharmaceuticals sector
    Swedish scientist behind Alzheimer’s drug has big ambitions

    Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s

  • Friday, 2 December, 2022
    The editorial board
    A glimmer of hope in treating Alzheimer’s disease

    Dementia drug development, diagnostics and delivery still require much more investment

  • Wednesday, 30 November, 2022
    Dementia
    Eisai says Alzheimer’s drug did not cause deaths of trial patients

    Japanese company refuses to rule out possibility treatment contributed to brain bleeds

  • Tuesday, 29 November, 2022
    Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug

    Shares fall 11% following two patient deaths in trials of lecanemab

  • Monday, 28 November, 2022
    LexDrugs research
    Dementia/Biogen: causal controversy means investors must take a stance Premium content

    The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down

  • Wednesday, 28 September, 2022
    Pharmaceuticals sector
    Biogen and Eisai shares surge after Alzheimer’s drug trial success

    Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease

  • Thursday, 21 July, 2022
    Special ReportJapan and Sustainability
    Drugmaker Eisai secures ESG money by linking investments to value

    ‘Hard numbers’ model designed by ex-head of finance is winning followers among leading investors and corporate Japan

  • Monday, 5 July, 2021
    News in-depthPharmaceuticals sector
    Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

    Hypothesis that brain plaques cause disease viewed with scepticism by some scientists

  • Wednesday, 16 June, 2021
    Pharmaceuticals sector
    Biogen’s Japanese partner calls for global action on Alzheimer’s

    Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’

  • Friday, 22 March, 2019
    Drugs research
    What next for Alzheimer’s research after latest drug failure?

    Biogen’s aducanumab was last hope of one approach to the disease, but there are others

  • Thursday, 21 March, 2019
    Drugs research
    Biogen shares slump on Alzheimer’s drug trial failure

    Drugmaker loses $18bn from market value after deciding to discontinue trials

  • Wednesday, 28 November, 2018
    Brexit
    Japanese ambassador to UK calls for pragmatism on Brexit talks
  • Monday, 19 November, 2018
    Brexit
    Pharma ignores the squabbling and prepares for a hard Brexit

    Costs are irrecoverable in industry that has to plan for all possible scenarios

  • Wednesday, 25 July, 2018
    Pharmaceuticals sector
    Biogen, Eisai Alzheimer’s drug slowed patients’ cognitive decline
  • Thursday, 5 July, 2018
    Pharmaceuticals sector
    Biogen, Eisai say Alzheimer’s drug succeeds in mid-stage trial
  • Thursday, 8 March, 2018
    LexPharmaceuticals sector
    Eisai/Merck: doubling up, and down Premium content

    Japanese group’s tie-up with US pharma on cancer drug will boost its research on Alzheimer’s

  • Thursday, 15 January, 2015
    The Big Read
    Healthcare: Counting the cost of cancer

    The cost of new drugs is pushing health budgets to the limit

  • Sunday, 11 January, 2015
    UK companies
    Drug companies call for overhaul of NHS cost-benefit evaluations

    Health service poised to stop paying for expensivecostly cancer therapies

  • Wednesday, 7 January, 2015
    Pharmaceuticals sector
    Drugmakers threaten NHS with lawsuits over cancer ruling

    Health service expected to stop paying for some expensive treatments

  • Monday, 27 May, 2013
    Pharmaceuticals sector
    Japan in pioneering partnership to fund global health research
  • Wednesday, 26 December, 2012
    Pharmaceuticals sector
    Pharma groups hope for diet drugs binge
  • Friday, 30 March, 2012
    World
    Confusing judgment with prejudice
Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

UK Edition

Subscribe for full access
  • Switch to International Edition

Top sections

  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • UK
    • UK Business & Economy
    • UK Politics & Policy
    • Brexit
    • UK Companies
    • Personal Finance
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Cryptofinance
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In